In an early-phase human trial involving FAP-IL-2v in combination with the anti-PD-L1 drug atezolizumab for patients with metastatic or recurrent cervical cancer, a favorable safety profile and significant anti-tumor activity were observed compared to approved PD-1 inhibitors (14). The gene discussed is FAP; the disease is cervical cancer.